Highlights • Transformational rebrand and product upgrade now in market which includes the world’s leading levels of DHA (Omega 3) for a major organic formula in addition to ARA and GOS • Rebrand to set a new platform for sustained revenue growth and a higher level of investment in China. This includes doubling Marketing spend and doubling the size of the China team in 2H19 • A normalised 1H19 Group Revenue result of $130m and EBITDA result of $26m largely reflects the net impact of lower revenue and an improved gross margin − Revenue impacted by a number of factors previously flagged to the market, including delayed SAMR registration, a planned reduction in trade inventory prior to the rebrand, and observed slowdown in category performance • The normalised result excludes an additional one-off $12m inventory provision for the rebrand transition. This provision accounts for all legacy product and is a material investment in rebrand and setting the right trade dynamics for early momentum • We retain a strong balance sheet with group cash increasing to $95m, zero debt levels and continued access to a $40m working capita
- Forums
- ASX - By Stock
- BAL
- Ann: 1H19 Results Announcement
Ann: 1H19 Results Announcement, page-3
-
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BAL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & Managing Director
Charles Armstrong
CEO & Managing Director
SPONSORED BY The Market Online